<DOC>
	<DOCNO>NCT01765192</DOCNO>
	<brief_summary>This study evaluate effect roflumilast 500 μg daily ( QD ) plus montelukast 10 mg QD versus 10 mg montelukast QD alone predose ( trough ) prebronchodilator force expiratory volume first second ( FEV1 ) .</brief_summary>
	<brief_title>Roflumilast Plus Montelukast Adults With Severe Asthma</brief_title>
	<detailed_description>The drug test study call roflumilast . Roflumilast test treat people asthma . This study look lung function asthma symptoms people take roflumilast combination montelukast .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement ( ie , follow clinical trial procedure Investigator instruction adequately ) . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Has document physician diagnosis severe asthma consistent global initiative asthma ( GINA ) step 4 clinical feature [ Gina 2011 ] least 6 month . 4 . Is male female age 18 year . 5 . Has treat fix free combination least mediumdose inhaled corticosteroid ( ICS ) ( ie , ≥ 250 µg fluticasone propionate daily equivalent ICS ) plus longacting beta agonist ( LABA ) least 3 month prior Screening stable ICS dose least 4 week Visit 2 . 6 . Shows GINAdefined uncontrolled asthma asthma control questionnaire ( ACQ7 ) score ≥1.5 despite least medium dose ICS/LABA therapy within 4 week prior Visit 1 ( Screening ) . 7 . Shows prebronchodilator FEV1 &gt; 55 % ≤ 85 % predict Visit 1 ( Screening ) . For participant perform induced sputum FEV1 must addition &gt; 1 liter . 8 . Has airway obstruction proven reversible improvement FEV1 least 12 % 200 mL inhalation shortacting bronchodilator . This either documented medical history ( support spirometry recording ) previous 12 month demonstrate screen Visit 1 ( Screening ) . 1 . Has receive investigational compound within 30 day prior start clinical trial participate active treatment phase another clinical trial persist pharmacodynamic effect trial treatment clinical trial exclude ( eg , participant well treatment free followup phase ) . 2 . Participation another clinical trial current trial . 3 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . Severe asthma exacerbation resolve 4 week prior Visit 1 , ( define need oral parenteral glucocorticosteroid intake least 3 day and/or hospitalization emergency room visit need oral parenteral corticosteroid use ) . 5 . Lower respiratory tract infection resolve 4 week prior Visit 1 . 6 . A diagnosis chronic obstructive pulmonary disease ( COPD ) ( base Global Initiative Chronic Obstructive Lung Disease [ GOLD ] criterion ) and/or relevant form lung disease ( eg , history primary bronchiectasis , cystic fibrosis , idiopathic ( pan ) bronchiolitis bronchiolitis obliterans , bronchopulmonary allergic aspergillosis , ChurgStrauss Syndrome , paradoxical vocal cord closure , lung resection , lung cancer , interstitial lung disease [ eg , fibrosis , silicosis , sarcoidosis ] , active tuberculosis ) may interfere evaluation treatment response . 7 . Current participation pulmonary rehabilitation program completion pulmonary rehabilitation program within 3 month precede Visit 1 . 8 . Has , judgment investigator , clinically significant abnormal laboratory value ( hematology biochemistry ) screen suggest undiagnosed disease require clinical evaluation . 9 . Has severe neuropsychiatric neurological disorder ( eg , history depression associate suicidal thinking , suicidal ideation behavior ) . 10 . Has congestive heart failure severity grade III IV accord New York Heart Association . 11 . Has symptomatic ischemic heart disease ( angina pectoris ) . 12 . Has hemodynamically significant cardiac arrhythmias heart valve deformation . 13 . Has liver impairment , define ChildPugh B/C and/or active viral hepatitis . 14 . Has severe immunological disease ( eg , multiple sclerosis , systemic lupus erythematosus , progressive multifocal leukoencephalopathy ) know infection human immunodeficiency virus ( HIV ) . 15 . Has severe acute infectious disease ( eg , tuberculosis , acute hepatitis ) . 16 . Has diagnosis malignant disease ( basal squamous cell carcinoma ) within 5 year prior Screening Visit 1 . 17 . Has history smoking within 1 year Visit 1 smoke history ≥10 pack year . 18 . Has history drug abuse ( define illicit drug use ) history alcohol abuse ( define regular daily consumption 2 alcoholic drink per day ) within past 1 year prior Screening visit . 19 . Has history clinically significant allergy idiosyncrasy roflumilast , montelukast inactive ingredient ( ) product , eg , rare hereditary problem galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption phenylketonuria . 20 . Has know highly unstable asthma define severe bronchoconstriction bronchoprovocation isotonic saline . 21 . Females childbearing potential willing use acceptable contraceptive method hormonal contraceptive ( oral , injection implant ) intrauterine contraceptive device start method less 2 month prior screen willing use double barrier method contraception ( diaphragm plus condom ) . 22 . If female , pregnant lactate intend become pregnant , , within 1 month participate study ; intend donate ova time period . 23 . Is required take exclude medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>